Given our strategic location in the heart of Maryland’s vibrant biotech landscape, and our unique access to speciality items such as Humira and other injectables, Blue Door Pharma has become the “go to” distributor for many procurement officers.
Blue Door Pharma’s current customers are primarily US-based biotech companies with a general focus on pharmaceutical and biopharmaceutical research and development, and include some of the leaders in the industry, all who appreciate the value, quality, and service we provide.
Similar to infliximab and etanercept, Adalimumab (Humira) binds to TNFα, preventing it from activating TNF receptors and is the third TNF inhibitor to be approved in the United States. Humira, however, was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein.
Humira has been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012 by the FDA in the disease’s management, it has been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn’s Disease.
Humira comes in three dosage forms: 1) 40 mg/0.8 mL in a single-use prefilled pen (HUMIRA Pen); 2) 40 mg/0.8 mL in a single-use prefilled glass syringe; and 3) 20 mg/0.4 mL in a single-use prefilled glass syringe. Contact Blue Door Pharma for current pricing and availability.